Ready-to-use vaccine and antibody blueprints for new viral threats
PROVIDENT: Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats
This project builds plug-and-play vaccine and antibody designs to help protect people from newly emerging enveloped RNA viruses like hantaviruses, nairoviruses, and paramyxoviruses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-11373848 on NIH RePORTER |
What this research studies
From a patient's perspective, PROVIDENT is working to create vaccine and therapeutic antibody designs that can be adapted quickly when new dangerous RNA viruses appear. Researchers will use laboratory studies and animal models to find the viral parts that trigger strong protective immune responses and to refine engineered antigens. The team will develop RNA vaccine candidates and candidate antibodies, and partner with industry to speed manufacturing and regulatory paths. Much of the current work is preclinical, so direct patient involvement would likely come later during clinical trials.
Who could benefit from this research
Good fit: Ideal participants for later-stage trials would include people at heightened risk of exposure to the targeted emerging viruses (for vaccine testing) and people with recent infection during an outbreak (for antibody treatment studies).
Not a fit: People not exposed to these specific emerging viruses or those with medical conditions that prevent typical vaccine responses may not directly benefit from this work.
Why it matters
Potential benefit: If successful, this work could shorten the time it takes to have safe vaccines and antibody treatments ready for new viral outbreaks.
How similar studies have performed: mRNA vaccines and therapeutic antibodies have proven effective for other viral threats (for example COVID-19), but applying standardized 'blueprints' across multiple emerging virus families is a newer and partly untested approach.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Chandran, Kartik — Albert Einstein College of Medicine
- Study coordinator: Chandran, Kartik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.